

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

**SECTION 1: IDENTIFICATION**

Product name : Cephapirin / Prednisolone Formulation

Other means of identification : Mastiplan (A011329)

**Manufacturer or supplier's details**

Company : Intervet Australia Pty Limited (trading as MSD Animal Health)

Address : 91-105 Harpin Street  
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Respiratory sensitisation : Category 1

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements :

**Prevention:**

P261 Avoid breathing mist or vapours.

P284 Wear respiratory protection.

**Response:**

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Peanut oil	8002-03-7	$\geq 60$ - $\leq 100$
Glyceryl monostearate	123-94-4	$< 10$
Cefapirin	21593-23-7	$\geq 0.1$ - $< 10$
prednisolone	50-24-8	$< 1$

**SECTION 4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).  
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

**SECTION 5. FIREFIGHTING MEASURES**

**Cephapirin / Prednisolone Formulation**

Version 3.1	Revision Date: 14.04.2025	SDS Number: 764044-00020	Date of last issue: 28.09.2024 Date of first issue: 16.06.2016
----------------	------------------------------	-----------------------------	---

---

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides  
Silicon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

**SECTION 7. HANDLING AND STORAGE**

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Peanut oil	8002-03-7	TWA (Mist)	10 mg/m <sup>3</sup>	AU OEL
Glyceryl monostearate	123-94-4	TWA	10 mg/m <sup>3</sup>	AU OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

## Cephapirin / Prednisolone Formulation

Version 3.1      Revision Date: 14.04.2025      SDS Number: 764044-00020      Date of last issue: 28.09.2024  
Date of first issue: 16.06.2016

		ter)		
Cefapirin	21593-23-7	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
Further information: RSEN				
prednisolone	50-24-8	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Combined particulates and organic vapour type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance** : liquid, oily

**Colour** : No data available

**Odour** : No data available

**Odour Threshold** : No data available

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Peanut oil:**

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 401 Remarks: Based on data from similar materials
---------------------	---	---

Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Remarks: Based on data from similar materials
-----------------------	---	--

**Glyceryl monostearate:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg Method: OECD Test Guideline 401 Remarks: Based on data from similar materials
---------------------	---	---

Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Remarks: Based on data from similar materials
-----------------------	---	--

**Cefapirin:**

Acute oral toxicity	:	LD50 (Mouse): 26,000 mg/kg
---------------------	---	----------------------------

Acute toxicity (other routes of administration)	:	LD50 (Mouse): > 7,600 mg/kg Application Route: Intraperitoneal  LD50 (Rat): 7,800 mg/kg Application Route: Intraperitoneal
---	---	--

**prednisolone:**

Acute oral toxicity	:	LD50 (Mouse): 1,680 mg/kg  LD50 (Rat): > 3,857 mg/kg
---------------------	---	--

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 147 mg/kg  
Application Route: Subcutaneous

LD50 (Mouse): 767 mg/kg  
Application Route: Intraperitoneal

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Peanut oil:**

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

**Glyceryl monostearate:**

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

**prednisolone:**

Remarks : No data available

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Peanut oil:**

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

**Glyceryl monostearate:**

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

**prednisolone:**

Remarks : No data available



**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Glyceryl monostearate:**

Test Type	: Buehler Test
Exposure routes	: Skin contact
Species	: Guinea pig
Result	: negative
Remarks	: Based on data from similar materials

**Cefapirin:**

Assessment	: Probability or evidence of high respiratory sensitisation rate in humans
------------	--

**prednisolone:**

Remarks	: No data available
---------	---------------------

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Peanut oil:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

**Glyceryl monostearate:**

Genotoxicity in vitro	: Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials
-----------------------	--

	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: Based on data from similar materials
--	--

	Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials
--	--

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

**Cefapirin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**prednisolone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

Test Type: sister chromatid exchange assay  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Rat  
Application Route: Oral  
Result: negative

Test Type: sister chromatid exchange assay  
Species: Humans  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****prednisolone:**

Species : Rat  
Application Route : Oral  
Exposure time : 18 Months  
Result : negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Glyceryl monostearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

**Cefapirin:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Intraperitoneal injection  
Fertility: LOAEL: > 500 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal injection  
Developmental Toxicity: LOAEL: > 200 mg/kg body weight

**prednisolone:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 1 mg/kg body weight  
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0.5 mg/kg body weight  
Result: Malformations were observed., Cleft palate

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 30 mg/kg body weight  
Result: decreased blood formation

Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: NOAEL: 25 mg/kg body weight  
Result: No effects on foetal development

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

Not classified based on available information.

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

**Components:****prednisolone:**

Target Organs	: Bone marrow, Adrenal gland, Liver
Assessment	: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Glyceryl monostearate:**

Species	: Rat
NOAEL	: $\geq 12,500$ mg/kg
Application Route	: Ingestion
Exposure time	: 84 Days
Remarks	: Based on data from similar materials

**Cefapirin:**

Species	: Rat
LOAEL	: $\geq 200$ mg/kg
Application Route	: Intraperitoneal
Target Organs	: Blood
Remarks	: anemia

Species	: Dog
LOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 4 Months
Target Organs	: Gastrointestinal tract

Species	: Dog
LOAEL	: 100 mg/kg
Application Route	: Intramuscular
Exposure time	: 10 Months
Target Organs	: Blood, Gastrointestinal tract
Remarks	: anemia

**prednisolone:**

Species	: Rat
LOAEL	: 0.6 mg/kg
Application Route	: Oral
Exposure time	: 63 Days
Target Organs	: Bone marrow

Species	: Dog
LOAEL	: 2.5 mg/kg
Application Route	: Oral
Exposure time	: 6 Weeks
Target Organs	: Adrenal gland

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

Species	: Rabbit
LOAEL	: 1 mg/kg
Application Route	: Oral
Exposure time	: 24 Weeks
Target Organs	: Liver

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Cefapirin:**

Ingestion : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis

**prednisolone:**

Ingestion : Symptoms: sodium retention, Headache, Vertigo, fluid retention, subcutaneous bleeding, striae, skin atrophy, menstrual irregularities

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Peanut oil:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10,000 mg/l  
Exposure time: 96 h  
Remarks: Based on data from similar materials

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
aquatic invertebrates Exposure time: 48 h  
Remarks: Based on data from similar materials

**Glyceryl monostearate:**

Toxicity to fish : LL50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

Toxicity to daphnia and other : EL50 (Daphnia magna (Water flea)): > 32 mg/l  
aquatic invertebrates Exposure time: 47 h  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: No toxicity at the limit of solubility  
Based on data from similar materials

Toxicity to algae/aquatic : EL50 (Pseudokirchneriella subcapitata (green algae)): > 100  
plants mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): > 0.22 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility  
Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 1 mg/l  
Exposure time: 18 h  
Remarks: Based on data from similar materials

**prednisolone:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 85 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 160 mg/l  
Exposure time: 72 h

EC50 (Pseudokirchneriella subcapitata (green algae)): > 160 mg/l  
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 0.23 mg/l  
Exposure time: 7 d

**Persistence and degradability****Components:****Glyceryl monostearate:**

Biodegradability : Result: Readily biodegradable.  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Glyceryl monostearate:**

Partition coefficient: n-octanol/water : log Pow: 6.1

## Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

**prednisolone:**

Partition coefficient: n-octanol/water : log Pow: 1.46

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : Not applicable

Proper shipping name : Not applicable

Class : Not applicable

Subsidiary risk : Not applicable

Packing group : Not applicable

Labels : Not applicable

Environmentally hazardous : no

**IATA-DGR**

UN/ID No. : Not applicable

Proper shipping name : Not applicable

Class : Not applicable

Subsidiary risk : Not applicable

Packing group : Not applicable

Labels : Not applicable

Packing instruction (cargo aircraft) : Not applicable

Packing instruction (passenger aircraft) : Not applicable

**IMDG-Code**

UN number : Not applicable

Proper shipping name : Not applicable

Class : Not applicable

Subsidiary risk : Not applicable

Packing group : Not applicable

Labels : Not applicable

EmS Code : Not applicable

Marine pollutant : Not applicable

**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****ADG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Hazchem Code	:	Not applicable

**Special precautions for user**

Not applicable

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Therapeutic Goods (Poisons Standard) Instrument	:	No poison schedule number allocated (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)
---	---	--

Prohibition/Licensing Requirements	:	There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.
------------------------------------	---	---

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

---

**SECTION 16: ANY OTHER RELEVANT INFORMATION****Further information**

Revision Date	:	14.04.2025
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a>

Date format	:	dd.mm.yyyy
-------------	---	------------

**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AU OEL	:	Australia. Workplace Exposure Standards for Airborne Con-



**Cephapirin / Prednisolone Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.1	14.04.2025	764044-00020	Date of first issue: 16.06.2016

---

taminants.

ACGIH / TWA	:	8-hour, time-weighted average
AU OEL / TWA	:	Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN